The Filing Desk

Keros Therapeutics vs Arcus Biosciences

Keros Therapeutics KROS · Arcus Biosciences RCUS · Biotechnology

Arcus Biosciences reported revenue of $247 million in fiscal 2025, about the same as Keros Therapeutics' $244 million in fiscal 2025. Keros Therapeutics had an operating margin of 27.7%, against -156.3% at Arcus Biosciences. Free cash flow was $106 million at Keros Therapeutics and −$484 million at Arcus Biosciences.

Side by side

Keros TherapeuticsArcus Biosciences
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$244M$247M
Revenue growth—−4.3%
Revenue growth a year, last 5 years—25.9%
Gross margin——
Operating margin27.7%−156.3%
Net margin35.7%−142.9%
Free cash flow$106M−$484M
Free cash flow margin43.5%−195.9%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$375M$0M
Change in diluted share count1.1%19.2%
Last close$11.39$15.78
P/E at the last close——
Insider trades, last 12 monthsbought $75,770, sold $506,996sold $9.0 million
Piotroski F-score—0 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Keros TherapeuticsArcus Biosciences
Operating margin
Percent of revenue
Keros TherapeuticsArcus Biosciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Keros TherapeuticsArcus Biosciences

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Keros Therapeutics and Arcus Biosciences pages.